Skip to content
Screener

Sarepta Therapeutics, Inc. SRPT Other income, net (Note 6)

Other income, net (Note 6) at other companies

Pfizer logo
PfizerPFE
$3.72B+603%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$245.3M-44.6%
PTC Therapeutics logo
PTC TherapeuticsPTCT
$1.61M+126%
Insmed logo
InsmedINSM
-$531K-217%
uniQure logo
uniQureQURE
-$15.97M
Wave Life Sciences logo
Wave Life SciencesWVE
-$275K-235%

Other financials

Income statement

See full
Revenue$401.3M-34.3%
Operating income$13.3M-88.5%
Net income-$4.9M-102%
EPS (diluted)-$0.05-103%

Balance sheet

See full
Cash & equivalents$571.1M+11.9%
Total debt$198.2M-7.6%
Total equity$1.5B+8.8%
Total assets$3.2B-13.4%

Cash flow

See full
Operating cash flow-$202.7M+65.3%
CapEx$555.0K-98.3%
Free cash flow-$204.8M+67.3%

Valuation

See full
Market cap$1.77B+10.9%
Enterprise value$1.4B+7.5%
P/S0.9×

Profitability

See full
Operating margin-50.8%-1.6pp
Net margin-6.9%
FCF margin-28.7%-9.2pp

Returns & leverage

See full
Return on equity-9.3%+2,662pp
Debt / equity0.1×0.0×
Current ratio4.4×+1.5×

Where this comes from

Reported directly by Sarepta Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:OtherNonoperatingIncomeExpense.

The source filing: Sarepta Therapeutics, Inc.’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 4:01 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-335003
Line itemFor the Three Months Ended June 30, 2026For the Three Months Ended June 30, 2025For the Six Months Ended June 30, 2026For the Six Months Ended June 30, 2025
Total cost and expenses387,960495,514760,3301,540,756
Operating income (loss)13,291115,577371,724(184,809)
Other (loss) income, net:
Other (expense) income, net(15,040)38,061(30,299)(45,071)
(Loss) income before income tax expense (benefit)(1,749)153,638341,425(229,880)
Income tax expense (benefit)3,141(43,254)15,35620,736
Net (loss) income$(4,890)$196,892$326,069$(250,616)
Other comprehensive (loss) income:

Item 1. Financial Statements

FAQ

What is Sarepta Therapeutics, Inc.'s other income, net (note 6)?
Sarepta Therapeutics, Inc. (SRPT) reported other income, net (note 6) of -$15.04M in Q2 2026.
How has Sarepta Therapeutics, Inc.'s other income, net (note 6) changed year-over-year?
Sarepta Therapeutics, Inc.'s other income, net (note 6) decreased by 139.5% year-over-year, from $38.06M to -$15.04M.
What does other income, net (note 6) mean?
This captures miscellaneous financial items that fall outside the scope of core operating activities, such as foreign exchange gains or losses, minor investment income, or non-recurring legal settlements. It serves as a catch-all for peripheral financial events that do not stem from the primary business operations. Investors monitor this to isolate core earnings from transient or incidental financial fluctuations.

Ask your AI about Sarepta Therapeutics, Inc.'s other income, net (note 6).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude